Clinical Trial

Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain

Study acronym: GTE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. The central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and/or chronicity of neuropathic pain.
Protocol Amendment History 1 change
critical Phase changed: Phase 1 -> Phase 2 2026-07-19
Trial Details
NCT Number NCT07682324
Lead Sponsor University of Alabama at Birmingham
Conditions Neuropathic Pain, Cancer Treatment
Enrollment 20 participants
Start Date 2026-09-30
Primary Completion 2029-01-08 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17